Aratana announces top-line results for dog osteoarthritis treatment

Aratana Therapeutics (PETX) says dogs that received AT-001 in a dose-ranging study of osteoarthritis "demonstrated improvements in pain assessment scores that were statistically significant compared to placebo."

The company plans to move the drug into a pivotal study next year and expects approval in 2016. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs